Project Grant R56AR080718
Award Date
9/18/23
Completion Date
8/31/24
Dollars Obligated
$313K
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This Project Grant award of $1,150,474 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to explore the cellular and molecular mechanisms driving large-scale bone regeneration. The research aims to unravel the intricate events necessary for extensive bone repair by investigating the role of a sentinel-type cell population marked by SOX9 expression in...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,938,605 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the Van Andel Research Institute (VAI) to investigate the mechanisms by which the X-linked chromatin modifying enzyme KDM5C regulates female bone mass. The goal is to determine how KDM5C transcriptionally programs genes that control osteoclast differentiation and function, and to assess whether KDM5C...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $412,756 to The University of Texas Southwestern Medical Center to conduct research on the mechanisms regulating bone healing and angiogenesis in osteonecrosis. The research aims to identify and define the critical Osterix-positive progenitor cell population responsible for the...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $361,300 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of North Carolina at Chapel Hill. The goal of this 2-year exploratory/developmental project is to use high-throughput small molecule screening and CRISPR screening technologies to identify signaling pathways and therapeutic targets for disease modification in osteoarthritis...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Vanderbilt University a $393,412 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop engineered cells as agents for treating osteoarthritis. The project aims to leverage advanced cell design platforms to create synthetic receptor-controlled, joint-resident cells that can detect cartilage degeneration and then upregulate the expression of transgenes to promote...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to investigate the mechanisms by which mechanical and hormonal signals interact within bone cells to stimulate bone formation. The $175,948 award, effective June 1, 2025 through May 31, 2030, will be conducted by The General Hospital Corporation, doing business as Massachusetts...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $667,125 to the University of Massachusetts Medical School (UMass Medical) to develop a long-lasting, bone-targeted gene therapy for treating osteogenesis imperfecta (OI), the most common bone fragility disease. The project aims to enhance bone-forming signaling pathways in OI patients by...
This $589,255 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) aims to develop small RNA targeting approaches, such as microRNA and siRNA, to advance treatments for heterotopic ossification (HO). HO is a condition involving pathologic bone formation in soft tissues that can occur following orthopedic surgeries or injuries. The award will fund the...
The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $783,176 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to Mayo Clinic to develop and validate a quantitative imaging methodology using photon-counting detector computed tomography (PCD-CT) for comprehensive assessment of bone quality in osteoporosis patients. The project aims to first develop and validate the PCD-CT imaging approach using...
This federal Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to elucidate the role of WNT16 signaling in chondrocyte biology and the development of osteoarthritis (OA), particularly in the context of hip OA and femoroacetabular impingement (FAI). The $644,887 award, which will be active from September 1, 2024 to August 31,...